Your browser doesn't support javascript.
loading
Mohs Micrographic Surgery for Facial Merkel Cell Carcinoma.
Nguyen, Brian J; Meer, Elana A; Bautista, Sana A; Kim, Diana H; Etzkorn, Jeremy R; McGeehan, Brendan; Miller, Christopher J; Briceno, Cesar A.
Afiliação
  • Nguyen BJ; 6572 Department of Ophthalmology, Scheie Eye Institute, University of Pennsylvania, PA, USA.
  • Meer EA; 6572 Department of Ophthalmology, Scheie Eye Institute, University of Pennsylvania, PA, USA.
  • Bautista SA; 6572 Department of Ophthalmology, Scheie Eye Institute, University of Pennsylvania, PA, USA.
  • Kim DH; 6572 Department of Ophthalmology, Scheie Eye Institute, University of Pennsylvania, PA, USA.
  • Etzkorn JR; 6572 Department of Dermatology, University of Pennsylvania, PA, USA.
  • McGeehan B; 6572 Department of Ophthalmology, Scheie Eye Institute, University of Pennsylvania, PA, USA.
  • Miller CJ; 6572 Department of Dermatology, University of Pennsylvania, PA, USA.
  • Briceno CA; 6572 Department of Ophthalmology, Scheie Eye Institute, University of Pennsylvania, PA, USA.
J Cutan Med Surg ; 27(1): 28-33, 2023.
Article em En | MEDLINE | ID: mdl-36471622
ABSTRACT

BACKGROUND:

Merkel cell carcinoma (MCC) is a rare malignant cutaneous tumor with frequent metastases. They often appear in the face where cosmetic and functional outcome is critical. Mohs micrographic surgery (MMS) is a controlled intervention that optimizes negative margins without sacrificing tissue.

OBJECTIVE:

A comprehensive assessment of outcomes of MMS-treated facial MCC will help guide clinicians in surgical and medical management. METHODS & MATERIALS Retrospective review identified facial MCC cases treated with MMS at a single institution from January 2005 to August 2020. Tumor characteristics and outcomes were recorded and descriptive and predictive analyses were performed.

RESULTS:

34 cases were reviewed with a mean followup of 34.4 months. The most common sites were the forehead, cheek-jaw region, and nasal ala. 2 (5.9%) patients had local recurrence by a mean of 4.3 months. No documented variables were significantly associated with local recurrence. 8 (23.5%) patients had progression to metastasis by a mean of 9.4 months. Younger age at biopsy and surgery, male sex, and intraoperative detection of in-transit disease were significantly associated with progression to metastasis.

CONCLUSIONS:

In summary, the tissue-sparing approach of MMS may be beneficial for MCC in cosmetically and functionally sensitive facial locations as it preserves tissue without compromising outcomes.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Cutâneas / Carcinoma de Célula de Merkel Tipo de estudo: Prognostic_studies Limite: Humans / Male Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Cutâneas / Carcinoma de Célula de Merkel Tipo de estudo: Prognostic_studies Limite: Humans / Male Idioma: En Ano de publicação: 2023 Tipo de documento: Article